Eastman Chemical (EMN) Stock Shrugs Off Stronger Q3 Earnings Momentum

Simply Wall St · 1d ago

Eastman Chemical just reported Q3 2026 earnings and the stock closed down 2.1% at US$66.51. The mood on the screen looks sour. The financials look more like a quiet grind higher in profitability than an earnings blowup.

Basic earnings per share landed at US$2.20 for the quarter on US$2.39b of revenue, while trailing P/E sits at 12.2x, below both industry and peer averages. The market is treating this as another ho-hum chemicals update. The income statement suggests traders may be leaning too hard into emotion and not enough into the margin story.

If you appreciate the earnings power at Eastman Chemical but prefer peers with similar value characteristics and even stronger balance sheets and cash generation, explore our curated list of list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs. Q3 2025): US$2,385m vs. US$2,202m (up about 8%)
  • Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$252m vs. US$47m (very large increase)
  • Basic EPS (Q3 2026 vs. Q3 2025): US$2.20 vs. US$0.41 (very large increase)
  • Trailing Net Profit Margin (Last 12 Months vs. Prior 12 Months): 6.9% vs. 7.7% (margin compression)

Ask Charlie what the DOE grant really changes for Eastman Chemical.

NYSE:EMN Trailing 12-Month Earnings & Revenue History as at Oct 2026
NYSE:EMN Trailing 12-Month Earnings & Revenue History as at Oct 2026

Evaluating Whether Eastman’s Circular Engine Is Delivering

Optimistic investors argue that Eastman Chemical can turn Kingsport into a growth engine rather than a science project.

"Bullish analysts expect Eastman Chemical to scale its Kingsport methanolysis and broader Renew platforms into a high margin growth engine, with circular and specialty products contributing a larger share of earnings over time."

Q3 and management commentary show real, if early, progress toward that goal. Renew revenue is tracking toward about US$100m in 2026 with roughly 20% incremental EBITDA margins. The reinstated US$375m DOE grant and the plan to expand Kingsport capacity while keeping CapEx within existing 2027 budgets mark clear execution milestones rather than just aspirational talk.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Eastman Chemical: Circular Scale-Up Meets Cash Flow Friction

The cautious view hangs on circular projects absorbing cash without delivering matching earnings. The core worry is clear.

"Although Eastman Chemical reports that Kingsport methanolysis is running at high yields with identified debottleneck capacity and meaningful EBITDA potential, capacity constraints and slower ramp up at rPET customers create a risk that future circular revenue falls short of what current capital deployed into recycling assets would need to support, which could pressure segment earnings and group return on invested capital."

Q3 shows circular revenue tracking toward about US$100m in 2026 with roughly 20% incremental EBITDA, which is tangible but still modest versus capital deployed. Operating cash flow guidance trimmed to about US$850m and the working capital drag reinforce that cash conversion remains a pressure point, so the bear concern on returns timing is not yet disproved.

Scan Beyond One Earnings Print

Eastman Chemical just showed how sentiment can drift away from the underlying margin story. The real opportunity is finding stocks that could be undervalued before the market corrects them.

  • Company 1 - 31% below our estimate - scales AI superclusters for high intensity workloads as customers adopt a second cloud backbone.
  • Company 2 - 41% below our estimate - rents composite access mats that keep long duration utility and pipeline projects moving over difficult terrain.
  • Company 3 - 34% below our estimate - supplies optical links and solar materials into multi year buildouts of data networks and domestic energy capacity.

That is three of the list. See the full list of 30 companies trading below our fair value estimates →